Swissmedic grants conditional marketing authorization for Novavax COVID-19 vaccine for individuals aged 18 years or older in Switzerland.
Novavax announced on April 13, 2022 that its COVID-19 vaccine Nuvaxovid has been granted conditional marketing authorization by Swissmedic, the Swiss Agency for Therapeutic Products, for active immunization to prevent COVID-19 in individuals aged 18 years or older. The vaccine will be the first protein-based COVID-19 vaccine authorized for use in Switzerland.
Novavax previously had an agreement with the government of Switzerland for up to six million doses of Novavax’ COVID-19 vaccine. The vaccine is a protein-based vaccine created using Novavax’ recombinant nanoparticle technology. Novavax has established partnerships for the manufacture, commercialization, and distribution of its vaccine worldwide. Existing authorizations leverage the company’s manufacturing parentship with Serum Institute of India, the world’s largest vaccine manufacturer by volume.
"We are proud that Switzerland is part of the growing list of countries to authorize Nuvaxovid and that people in Switzerland will have a protein-based COVID-19 vaccine option," said Stanley C. Erck, President and CEO of Novavax. "As we continue to fight COVID-19, we think it is incredibly important that people have a choice in vaccine options. Nuvaxovid offers something different from the current portfolio of vaccines by using a more tried and tested technology platform, while still providing a strong efficacy and safety profile."
Source: Novavax
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
2 Commerce Drive
Cranbury, NJ 08512